Study S001903

Effects on Re-endothelialisation With Bydureon Treatment Add on to Insulin Versus Insulin Alone, Both in Combination With Metformin in Type 2 Diabetic Subjects

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT02621489
Acronym: Rebuild
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: NONE
Status: COMPLETED
Enrollment: 38
Start: 2015-12
Primary completion: 2022-08
Lead sponsor: Karolinska Institutet
Conditions: Atherosclerosis; Diabetes; Restenosis
Interventions: DRUG:Bydureon; DRUG:Humulin kwickpen; DRUG:Metformin
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

The degree of non-covered stent struts by Bydureon add on to Insulin over that of Insulin as analyzed by optical coherence tomography (OCT). [12 weeks]

Linked records (5)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0014366	Effects of exenatide on coronary stent's endothelialization in subjects with type 2 diabetes: a randomized controlled trial. The Rebuild study. Santos-Pardo I, Cardiovascular diabetology	2023	Randomized trial	PMID 38066597 DOI	cites ClinicalTrials.gov:NCT02621489; registry reference DERIVED:38066597
R0017908	Glucagon-Like Peptide-1 Receptor Activation Does not Affect Re-Endothelialization but Reduces Intimal Hyperplasia via Direct Effects on Smooth Muscle Cells in a Nondiabetic Model of Arterial Injury. Eriksson L, Journal of vascular research	2015	Preclinical	PMID 25966620 DOI	registry reference RESULT:25966620
R0021948	Exendin-4 protects endothelial cells from lipoapoptosis by PKA, PI3K, eNOS, p38 MAPK, and JNK pathways. Erdogdu O, Journal of molecular endocrinology	2013	Other	PMID 23343509 DOI	registry reference RESULT:23343509
R0019316	Exendin-4 restores glucolipotoxicity-induced gene expression in human coronary artery endothelial cells. Erdogdu Ö, Biochemical and biophysical research communications	2012	Preclinical	PMID 22390929 DOI	registry reference RESULT:22390929
R0022961	Exendin-4 stimulates proliferation of human coronary artery endothelial cells through eNOS-, PKA- and PI3K/Akt-dependent pathways and requires GLP-1 receptor. Erdogdu O, Molecular and cellular endocrinology	2010	Other	PMID 20452396 DOI	registry reference RESULT:20452396